Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have received an average rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $11.80.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 4th. ValuEngine lowered Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Finally, Oppenheimer set a $14.00 price target on Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 1st.
Several institutional investors and hedge funds have recently bought and sold shares of CNAT. Wells Fargo & Company MN increased its holdings in Conatus Pharmaceuticals by 63.4% in the 1st quarter. Wells Fargo & Company MN now owns 55,600 shares of the biotechnology company’s stock worth $326,000 after buying an additional 21,564 shares in the last quarter. BlackRock Inc. increased its holdings in Conatus Pharmaceuticals by 45.4% in the 1st quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock worth $13,601,000 after buying an additional 723,413 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Conatus Pharmaceuticals by 1,205.7% in the 1st quarter. JPMorgan Chase & Co. now owns 74,062 shares of the biotechnology company’s stock worth $435,000 after buying an additional 68,390 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Conatus Pharmaceuticals by 253.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock worth $135,000 after buying an additional 16,476 shares in the last quarter. Finally, LMR Partners LLP bought a new stake in Conatus Pharmaceuticals in the 2nd quarter worth about $311,000. 33.50% of the stock is owned by hedge funds and other institutional investors.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.05. The firm had revenue of $8.77 million during the quarter, compared to analyst estimates of $9.06 million. Conatus Pharmaceuticals had a negative return on equity of 69.68% and a negative net margin of 48.46%. As a group, sell-side analysts anticipate that Conatus Pharmaceuticals will post -0.61 EPS for the current year.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.